Statements (40)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Roche_acquired_Chugai_Pharmaceutical_in_2002
|
| gptkbp:awards |
received the 2020 Good Design Award
received the 2021 Japan Healthcare Award received the 2022 Pharmaceutical Technology Award received the 2023 Innovation Award |
| gptkbp:clinicalTrials |
conducts clinical trials globally
|
| gptkbp:communityEngagement |
supports educational programs
engages in community health initiatives donates to health-related charities sponsors medical research grants participates in environmental sustainability efforts |
| gptkbp:employees |
approximately 7,000
|
| gptkbp:founded |
1943
|
| gptkbp:founder |
gptkb:Kiyoshi_Chugai
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chugai Pharmaceutical
|
| gptkbp:parentCompany |
gptkb:Roche
|
| gptkbp:partnerships |
collaborates_with_Amgen
collaborates_with_Chugai_Pharmaceutical_USA collaborates_with_Genentech |
| gptkbp:products |
gptkb:Atezolizumab
Bevacizumab Tocilizumab Rituximab Trastuzumab |
| gptkbp:researchFocus |
oncology
rare diseases neuroscience immunology |
| gptkbp:revenue |
¥ 1.1 trillion (2020)
|
| gptkbp:specializesIn |
biopharmaceuticals
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4519
|
| gptkbp:subsidiary |
gptkb:Chugai_Pharma_Europe
gptkb:Chugai_Pharma_Singapore gptkb:Chugai_Pharma_China gptkb:Chugai_Pharma_USA gptkb:Chugai_Pharma_Korea |
| gptkbp:website |
www.chugai-pharm.co.jp
|